Loading...
•
Jun 30, 2024
Nektar Q2 2024 Earnings Report
Nektar's financial performance for Q2 2024 was reported.
Key Takeaways
Nektar Therapeutics reported revenue of $23.5 million and a net loss of $52.4 million for the second quarter of 2024. The company's cash and investments are expected to support operations into the third quarter of 2026.
Revenue for the second quarter of 2024 was $23.5 million, compared to $20.5 million in the second quarter of 2023.
Net loss for the second quarter of 2024 was $52.4 million, or $0.25 loss per share, compared to a net loss of $51.1 million, or $0.27 loss per share in the second quarter of 2023.
Cash and investments in marketable securities were $290.6 million as of June 30, 2024.
Enrollment is on track for topline data in the first half of 2025 for atopic dermatitis and topline data in mid-2025 for alopecia areata.
Forward Guidance
Nektar expects its cash and marketable securities to support strategic development activities and operations into the third quarter of 2026.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...